Orlistat-associated adverse effects and drug interactions: a critical review

TD Filippatos, CS Derdemezis, IF Gazi, ES Nakou… - Drug safety, 2008 - Springer
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of
the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), …

[HTML][HTML] Adverse effects of GLP-1 receptor agonists

TD Filippatos, TV Panagiotopoulou… - The review of diabetic …, 2014 - ncbi.nlm.nih.gov
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic
drugs that improve glycemic control and many other atherosclerosis-related parameters in …

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and …

…, V Athyros, M Elisaf, TD Filippatos… - Journal of …, 2018 - journals.lww.com
Obesity predisposes for atrial fibrillation, heart failure, sudden cardiac death, renal disease
and ischemic stroke, which are the main causes of cardiovascular hospitalization and …

A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease

AA Kei, TD Filippatos, V Tsimihodimos, MS Elisaf - Metabolism, 2012 - Elsevier
The focus of this review is on the role of apolipoprotein C-II (apoC-II) in lipoprotein metabolism
and the potential effects on the risk of cardiovascular disease (CVD). We searched …

Hyponatremia in the elderly: challenges and solutions

TD Filippatos, A Makri, MS Elisaf… - Clinical interventions in …, 2017 - Taylor & Francis
Decreased serum sodium concentration is a rather frequent electrolyte disorder in the
elderly population because of the presence of factors contributing to increased antidiuretic …

Statin-associated adverse effects beyond muscle and liver toxicity

DN Kiortsis, TD Filippatos, DP Mikhailidis, MS Elisaf… - Atherosclerosis, 2007 - Elsevier
Randomized controlled trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) have consistently demonstrated significant reductions in …

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses

TD Filippatos, A Liontos, I Papakitsou… - Postgraduate …, 2019 - Taylor & Francis
Sodium-glucose co-transporter 2 (SGLT2) inhibitors inhibit glucose re-absorption in the
proximal renal tubules. Two trials have shown significant reductions of cardiovascular (CV) …

Increased plasma visfatin levels in subjects with the metabolic syndrome.

TD Filippatos, CS Derdemezis, IF Gazi… - European Journal of …, 2008 - europepmc.org
Filippatos TD , … Filippatos TD | 0000-0002-1713-0923 …

MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment

G Liamis, TD Filippatos, A Liontos… - European Journal of …, 2017 - academic.oup.com
Background Patients with moderate to severe hypothyroidism and mainly patients with
myxedema may exhibit reduced sodium levels (<135 mmol/L). Summary The aim of this short …

Visfatin/PBEF and atherosclerosis-related diseases

TD Filippatos, HS Randeva… - Current vascular …, 2010 - ingentaconnect.com
Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also
ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine …